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Medical management of osteogenesis imperfecta (OI), a
genetic disorder of connective tissue characterized by
reduced bone mass and frequent fractures, is focused on
maximizing patients’ mobility and function. Many meth-
ods of pharmacological treatment have been introduced
for the severe forms of OI, including calcium, anabolic
steroids, growth hormone, and calcitonin, without con-
sistent benefit. Recent studies reported beneficial effect
of intravenous and oral bisphosphonates on moderate to
severe form of OI in children.
This report is to review OI cases in Indonesian children
and to know the effect of bisphosphonate treatment for
them.
Data on age, gender, age at diagnosis, availability of
bisphosphonate treatment, and its effects were collected
from Indonesian OI children registry, which documented
from April to June 2012. Fourteen centers which have
members of pediatric endocrinology chapter, Indonesian
Pediatric society, were involved in obtaining data for the
registry.
Forty-six OI cases (17 female), who were diagnosed at
the age of 7 days-11 years old and mostly categorized as
type 3 of OI, were recorded. Two patients were died
before commencing treatment. There were twenty-seven
(27/46) patients received bisphosphonates, which were
administered to moderate to severe cases. Two patients,
who were treated, were died due to hyperthermia after
the first day of pamidronate infusion, and pneumonia
aspiration. Twenty-five patients received intravenous
pamidronate and 3 oral alendronate. Liver and renal
function test, and serum electrolyte were evaluated
before and after treatment. Most patients reported
decreased irritability, increased muscle tone and mobi-
lity. In addition, despite hyperthermia in one case, no
serious adverse effects documented. Although some
patients had government health insurance for the poor,
unfortunately, the medicine, which is considered expen-
sive for the patients, is not yet included in the drug list
of government insurance.
Most of registered OI cases in Indonesian children
were type 3. More than half of the cases underwent
treatment with bisphosphonates with beneficial effects,
although long-term follow up and well-documented data
are required.
Authors’ details
1Department of Pediatrics, School of Medicine, Airlangga University, dr
Soetomo Hospital, Surabaya, Indonesia. 2Eijkman Institute for Molecular
Biology, Jakarta, Indonesia. 3Department of Pediatrics, School of Medicine,
Andalas University, Muhammad Djamil Hospital, Padang, Indonesia.
4Department of Child Health, Faculty of Medicine, University of Indonesia,
Ciptomangunkusumo Hospital, Jakarta, Indonesia.
Published: 3 October 2013
doi:10.1186/1687-9856-2013-S1-P166
Cite this article as: Rochmah et al.: Osteogenesis imperfecta in children:
Indosesian experiences. International Journal of Pediatric Endocrinology
2013 2013(Suppl 1):P166.
1Department of Pediatrics, School of Medicine, Airlangga University, dr
Soetomo Hospital, Surabaya, Indonesia
Full list of author information is available at the end of the article
Rochmah et al. International Journal of Pediatric Endocrinology 2013, 2013(Suppl 1):P166
http://www.ijpeonline.com/content/2013/S1/P166
© 2013 Rochmah et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
